Group Leader & Associate Professor | BRIC–@UCPH_Research & Finsen Lab–@Rigshospitalet | Tumor evolution & drug resistance | Former MGH/@harvardmed | Catalan
Copenhagen (Denmark)
Joined April 2015
- Tweets1.5K
- Following2.2K
- Followers619
- Likes22.2K
Pinned Tweet
Happy to report the first clinical evidence revealing how tumors develop resistance to p53-Y220C reactivators out today @CD_AACR @MassGenBrigham @harvardmed #CorcoranLab #Rezatapopt #p53Y220C #PYNNACLE
aacrjournals.org/cancerdisco…
A record 7,710 proposals – a 60.4% increase to 2026 – for #ERCStG 2027! Physical Sciences & Engineering are in the lead (43%), followed by Social Sciences & Humanities (29%), and Life Sciences (28%).
erc.europa.eu/news-events/ne…
129
Topoisomerase inhibitor vs. a B7-H3-targeting ADC linked to a topoisomerase inhibitor payload 🤯
Good news for the #SCLC community! @SclcSMASHERS @NEJM #Phase3
nejm.org/doi/full/10.1056/NE…
“Women living with #mBC face an uphill battle as their tumors evolve to escape treatment. This marks the first FDA approval guided by the detection of a resistance mutation in ctDNA before imaging tests show that the disease is progressing." #SERENA6 #ESR1
fda.gov/news-events/press-an…
1
130
Melanoma to rhabdomyosarcoma transformation after ICB and HDAC-i. Let's talk about tumor evolution under treatment pressure 🤯 @MedCellPress
cell.com/med/abstract/S2666-…
2
204
@CarrerasIJC i @GTRecerca impulsen dues noves iniciatives per fomentar l’ús del català en entorns científics internacionalitzats! 💯💯💯
carrerasresearch.org/ca/noti…
1
73
When they tell you "the lab is like a family"...Just run away, your family is at home waiting for you to share dinner. Thank me later! @AcademicChatter
@PostdocVoice
science.org/content/article/…
1
217
Two weeks left to apply for our Research Assistant & Lab Manager position! Join a growing translational cancer research group 🔬🧬 #Copenhagen #FinsenLaboratory @Rigshospitalet @jobRxiv @ScienceCareers
For further information and application details ⬇️
candidate.hr-manager.net/App…
🤖 Made with AI
171
Resistance to mutant p53 reactivation: Precision enables elegant molecular solutions, but in the evolutionary arms race between therapy and tumor, it may also become the Achilles’ heel that limits long-term efficacy #ResearchHighlight #Y220C @sigtrans_sttt
nature.com/articles/s41392-0…
Great initiative! #PRECISE
nature.com/articles/s41588-0…
175
#Daraxonrasib 👏🏼👏🏼👏🏼
A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer.
In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy.
While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers.
As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”
Congratulations to the researchers and patients who made this important progress possible. 👏👏👏
Video Courtesy: @asco
The wait is over 🤯🤯🤯
Daraxonrasib in 2nd line metPDAC doubles OS compared to chemotherapy. Concurrent publication at @NEJM: nejm.org/doi/full/10.1056/NE…
Congrats to everyone involved in the #RASolute302 study! #ASCO26 @KRASKickers @RevMedicines #pancsm #KRAS
